Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06139523 · ClinicalTrials.gov registry record
Optimize Pediatric OCT Imaging
A clinical trial of Glaucoma and Retinal Disease, sponsored by Duke University.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06139523: Recruiting study of Glaucoma and Retinal Disease, sponsored by Duke University.
NCT06139523 is a study of Glaucoma and Retinal Disease that is actively recruiting participants, run by Duke University. The registered enrollment target is 30 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06139523, a study of Glaucoma and Retinal Disease, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina. The investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).
Conditions Studied
Interventions
- DEVICE Investigational contact OCT system
- DEVICE Investigational noncontact OCT system:
Study Locations (1)
North Carolina
- Duke University Eye Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2026-12 |
What NCT06139523 shows while recruiting
NCT06139523 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Investigational contact OCT system is the first listed.
NCT06139523 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06139523 about?
NCT06139523 is a clinical study titled "Optimize Pediatric OCT Imaging". Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ...
What is the current status of trial NCT06139523?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-01-24. Estimated completion is 2026-12.
What conditions does trial NCT06139523 study?
This clinical trial studies the following conditions: Glaucoma, Retinal Disease, Optic Nerve Diseases.
What interventions are being tested in trial NCT06139523?
The interventions under investigation include: Investigational contact OCT system (DEVICE), Investigational noncontact OCT system: (DEVICE).
Who is sponsoring clinical trial NCT06139523?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06139523 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06139523's enrollment target sits among peer trials
30 79th of 92 higher than 11 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Eye Pressure Lowering Surgery
RECRUITING
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI